Mena Botros, MD
Pulmonary Disease · Houston, TXNPI 1558757104
Payments from drug & device makers
Across 72 payments — averaging $463.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$31K
- Insmed, Inc.$600
- Boehringer Ingelheim$436
- Actelion Pharmaceuticals US, Inc.$228
- GSK$188
- Takeda Pharmaceuticals U.S.A., Inc.$178
- plus $415 from 8 others
What the payments were for
- Food & beverage$1,88191%
- Education$1799%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 5 | $31,336 |
| Insmed, Inc. | 26 | $600 |
| Boehringer Ingelheim | 16 | $436 |
| Actelion Pharmaceuticals US, Inc. | 2 | $228 |
| GSK | 8 | $188 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $178 |
| Paragonix Technologies, Inc. | 3 | $160 |
| Genentech USA, Inc. | 1 | $100 |
| Pulmonx Corporation | 2 | $53 |
| Astellas Pharma US Inc | 1 | $27 |
| Grifols USA, LLC | 1 | $20 |
| Sandoz | 1 | $19 |
| Pharming Healthcare, Inc. | 1 | $19 |
| United Therapeutics Corporation | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPSUMIT$149
- LIVTENCITY$119
How this compares
$33,382 in reported general payments places this provider in the 85th percentile of 904 pulmonary disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 32 | $234,813 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 25 | $220,371 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 19 | $141,828 |
| PrevymisLetermovir | 13 | $92,277 |
| CresembaIsavuconazonium Sulfate | 14 | $89,020 |
| GammakedImmune Globul G/Gly/Iga Avg 46 | 24 | $57,984 |
| EliquisApixaban | 67 | $46,811 |
| Atovaquone | 93 | $44,808 |
| Posaconazole | 30 | $34,164 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $27,688 |
| Voriconazole | 63 | $27,438 |
| Valganciclovir Hcl | 97 | $24,454 |
| Tacrolimus | 153 | $16,140 |
| Mycophenolic AcidMycophenolate Sodium | 43 | $14,599 |
| Envarsus XrTacrolimus | 19 | $13,822 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $178 | $234,81332 claims |
| Grifols USA, LLCGamunex-C | $20 | $141,82819 claims |
| Astellas Pharma US IncCresemba | $27 | $89,02014 claims |
| PfizerEliquis | $31,336 | $46,81167 claims |
| GSKTrelegy Ellipta | $188 | $27,68829 claims |
| SandozEnoxaparin Sodium | $19 | $7,54332 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 904 pulmonary disease providers in Texas.
Other pulmonary disease in Houston
- Ivan RosasHouston$13.8M
- Nicola HananiaHouston$2.2M
- Sandeep SahayHouston$2.1M
- Zeenat SafdarHouston$1.7M
- Howard HuangHouston$1.3M
- Dileep PuppalaHouston$1.1M
- Sandeep GuptaHouston$1.1M
- Joseph VaronHouston$1.1M
- Bela PatelHouston$974K
- Roberto CasalHouston$865K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.